Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Neovascular(Wet) Age Related Macular Degeneration”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT05439629
What this trial is testing

Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration

Who this might be right for
Neovascular (Wet) Age-related Macular Degeneration
Bio-Thera Solutions 488
Large-scale testing (Phase 3)Study completedNCT04480463
What this trial is testing

Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD)

Who this might be right for
Wet Age-related Macular DegenerationNeovascular Age-related Macular Degeneration
Sam Chun Dang Pharm. Co. Ltd. 576
Testing effectiveness (Phase 2)Study completedNCT01678963
What this trial is testing

Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)

Who this might be right for
Neovascular Age Related Macular Degeneration
Ohr Pharmaceutical Inc. 142
Early research (Phase 1)Study completedNCT01997164
What this trial is testing

Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular ("Wet") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)

Who this might be right for
Neovascular Age-Related Macular DegenerationDiabetic Macular Edema
Regeneron Pharmaceuticals 20
Large-scale testing (Phase 3)WithdrawnNCT02036723
What this trial is testing

Safety and Efficacy Study of BCD-021 Compared to Lucentis® in Patients With Neovascular Wet Age-related Macular Degeneration

Who this might be right for
Wet Age-related Macular Degeneration
Biocad
Not applicableLooking for participantsNCT02253030
What this trial is testing

OCT Angiography in Wet AMD

Who this might be right for
Neovascular (Wet) Age-related Macular Degeneration (AMD)
Oregon Health and Science University 160
Early research (Phase 1)Study completedNCT04635800
What this trial is testing

Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients

Who this might be right for
Macular EdemaDiabetic Macular EdemaNeovascular Age-related Macular Degeneration+1 more
Novartis Pharmaceuticals 21
Not applicableStudy completedNCT05211804
What this trial is testing

Mechanisms of Retinal Revascularization and Clinical Indicators of Neovascular AMD Relapse

Who this might be right for
Wet Macular Degeneration
Sorlandet Hospital HF 31
Early research (Phase 1)Study completedNCT02061865
What this trial is testing

Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMD

Who this might be right for
Neovascular Wet Age-related Macular Degeneration (AMD)
Regeneron Pharmaceuticals 12
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07766473
What this trial is testing

First in Human Study of BETA-TT8 in wetAge-related Macular Degeneration (wetAMD)

Who this might be right for
Neovascular (Wet) Age-Related Macular Degeneration
Filamon LTD 24
Large-scale testing (Phase 3)Ended earlyNCT04049266
What this trial is testing

Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.

Who this might be right for
Wet Macular Degeneration
Kodiak Sciences Inc 559
Post-approval studies (Phase 4)Study completedNCT02246829
What this trial is testing

Assessment of Early Changes in SD-OCT After Initiation of a Treatment by Intravitreal Aflibercept (EYLEA®)START

Who this might be right for
Neovascular Age-related Macular Degeneration of All Subtypes
University Hospital, Bordeaux 50
Not applicableNot Yet RecruitingNCT07328776
What this trial is testing

AI vs. Physician for Anti-VEGF Decision-Making: An RCT

Who this might be right for
DMERetinal Vein Occlusion (RVO)Neovascular (Wet) Age-Related Macular Degeneration
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine 200
Early research (Phase 1)Study completedNCT01024998
What this trial is testing

Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD)

Who this might be right for
Macular DegenerationAge-Related MaculopathiesAge-Related Maculopathy+7 more
Genzyme, a Sanofi Company 19
Not applicableNot Yet RecruitingNCT07567898
What this trial is testing

Effectiveness of Multidisciplinary Protocolised Interventions on IVT Non-adherence Rates

Who this might be right for
Diabetic Macular EdemaNeovascular (Wet) Age-Related Macular DegenerationIntravitreal Injection
Singapore Eye Research Institute 200
Post-approval studies (Phase 4)Ended earlyNCT05473715
What this trial is testing

Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment

Who this might be right for
Neovascular (Wet) Age-related Macular Degeneration
Bayer 3
Not applicableNot Yet RecruitingNCT07744204
What this trial is testing

LEAP Strategy for Neovascular Age-Related Macular Degeneration

Who this might be right for
Neovascular Age-related Macular Degeneration(nAMD)Wet Macular Degeneration
Chinese PLA General Hospital 240
Large-scale testing (Phase 3)Not Yet RecruitingNCT07520318
What this trial is testing

This is a 96-week, Multicenter Study in Patients With Neovascular AMD That Evaluates OCUL101 for Efficacy, Safety, Durability, and Pharmacokinetics, Comparing it With Another Treatment. The Study Will be Conducted in Two Parts, Part A and Part B.

Who this might be right for
Adults With Neovascular Age-related Macular Degeneration
Shenzhen Oculgen Biomedical Technology Co., Ltd. 255
Not applicableStudy completedNCT01712035
What this trial is testing

Neovascular Age-related Macular Degeneration

Who this might be right for
Neovascular Age-related Macular Degeneration
Oregon Health and Science University 44
Large-scale testing (Phase 3)Study completedNCT00469352
What this trial is testing

Genetic and Environmental Factors and Their Effect on Response to Treatment With Lucentis (Ranibizumab) for Wet AMD

Who this might be right for
Macular Degeneration
Oregon Health and Science University 150
Next Page